HRP20130220T1 - Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih - Google Patents
Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih Download PDFInfo
- Publication number
- HRP20130220T1 HRP20130220T1 HRP20130220TT HRP20130220T HRP20130220T1 HR P20130220 T1 HRP20130220 T1 HR P20130220T1 HR P20130220T T HRP20130220T T HR P20130220TT HR P20130220 T HRP20130220 T HR P20130220T HR P20130220 T1 HRP20130220 T1 HR P20130220T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- methyl
- fluorophenyl
- hydroxyimino
- bromo
- Prior art date
Links
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 title claims 3
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 title claims 3
- 238000000034 method Methods 0.000 title claims 3
- -1 C2-4 akynyl Chemical group 0.000 claims 296
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 162
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 161
- 150000001875 compounds Chemical class 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 37
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 23
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 23
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims 20
- 125000001072 heteroaryl group Chemical group 0.000 claims 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 19
- 125000001475 halogen functional group Chemical group 0.000 claims 15
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 14
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 12
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims 10
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 10
- 101100478314 Caenorhabditis elegans sre-1 gene Proteins 0.000 claims 9
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 6
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 4
- 229960003966 nicotinamide Drugs 0.000 claims 4
- 235000005152 nicotinamide Nutrition 0.000 claims 4
- 239000011570 nicotinamide Substances 0.000 claims 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- BIUDHHGROGJSHN-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)benzaldehyde Chemical group FC1=CC=C(C=O)C=C1C(F)(F)F BIUDHHGROGJSHN-UHFFFAOYSA-N 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 101100038645 Streptomyces griseus rppA gene Proteins 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- RQCYTRBQQPBHHH-UHFFFAOYSA-N 1-[4-[N'-(3-bromo-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1,2,5-oxadiazol-3-yl]-3-(2-phenylethyl)urea Chemical compound N=1ON=C(NC(=O)NCCC=2C=CC=CC=2)C=1C(=NO)NC1=CC=C(F)C(Br)=C1 RQCYTRBQQPBHHH-UHFFFAOYSA-N 0.000 claims 1
- ZXVHSOFBPHNUBB-UHFFFAOYSA-N 1-[4-[N'-(3-bromo-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1,2,5-oxadiazol-3-yl]-3-(3-cyanophenyl)urea Chemical compound N=1ON=C(NC(=O)NC=2C=C(C=CC=2)C#N)C=1C(=NO)NC1=CC=C(F)C(Br)=C1 ZXVHSOFBPHNUBB-UHFFFAOYSA-N 0.000 claims 1
- CFUVGMXXDOHZSS-UHFFFAOYSA-N 1-[4-[N'-(3-bromo-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1,2,5-oxadiazol-3-yl]-3-cyclopentylurea Chemical compound N=1ON=C(NC(=O)NC2CCCC2)C=1C(=NO)NC1=CC=C(F)C(Br)=C1 CFUVGMXXDOHZSS-UHFFFAOYSA-N 0.000 claims 1
- DPVWRXHQQCLFSP-UHFFFAOYSA-N 1-[4-[n-(3-chlorophenyl)-n-hydroxycarbamimidoyl]-1,2,5-oxadiazol-3-yl]-3-phenylurea Chemical compound C=1C=CC(Cl)=CC=1N(O)C(=N)C1=NON=C1NC(=O)NC1=CC=CC=C1 DPVWRXHQQCLFSP-UHFFFAOYSA-N 0.000 claims 1
- REBMSSRAXRRVMS-UHFFFAOYSA-N 1-benzyl-3-[4-[n-(3-bromo-4-fluorophenyl)-n-hydroxycarbamimidoyl]-1,2,5-oxadiazol-3-yl]-1-methylurea Chemical compound N=1ON=C(C(=N)N(O)C=2C=C(Br)C(F)=CC=2)C=1NC(=O)N(C)CC1=CC=CC=C1 REBMSSRAXRRVMS-UHFFFAOYSA-N 0.000 claims 1
- VVGIBOCLVOAKRW-UHFFFAOYSA-N 3-[4-[N'-(3-bromo-4-fluorophenyl)-N-hydroxycarbamimidoyl]-1,2,5-oxadiazol-3-yl]-1-(3-cyanophenyl)-1-methylurea Chemical compound C=1C=CC(C#N)=CC=1N(C)C(=O)NC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 VVGIBOCLVOAKRW-UHFFFAOYSA-N 0.000 claims 1
- XTEBFDOOXBYXAZ-UHFFFAOYSA-N 4-(benzylamino)-N'-(3-bromo-4-fluorophenyl)-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide Chemical compound N=1ON=C(NCC=2C=CC=CC=2)C=1C(=NO)NC1=CC=C(F)C(Br)=C1 XTEBFDOOXBYXAZ-UHFFFAOYSA-N 0.000 claims 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims 1
- 101100162203 Aspergillus parasiticus (strain ATCC 56775 / NRRL 5862 / SRRC 143 / SU-1) aflG gene Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- SEILHVYWYMULHC-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(=O)NC=1C(=NON=1)C(N(O)C1=CC(=C(C=C1)F)Br)=N Chemical compound C(C1=CC=CC=C1)NC(=O)NC=1C(=NON=1)C(N(O)C1=CC(=C(C=C1)F)Br)=N SEILHVYWYMULHC-UHFFFAOYSA-N 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- LJMUSXSQASVGPI-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-(pyridin-4-ylmethylamino)-1,2,5-oxadiazole-3-carboximidamide Chemical compound N=1ON=C(NCC=2C=CN=CC=2)C=1C(=NO)NC1=CC=C(F)C(Br)=C1 LJMUSXSQASVGPI-UHFFFAOYSA-N 0.000 claims 1
- OLQLOKUCVPVXCR-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[(1-methylpiperidin-4-yl)methylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound C1CN(C)CCC1CNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 OLQLOKUCVPVXCR-UHFFFAOYSA-N 0.000 claims 1
- MTOQTNOOUHGNNT-UHFFFAOYSA-N N-(3-bromo-4-fluorophenyl)-N-hydroxy-4-(1,3-thiazol-4-ylmethylamino)-1,2,5-oxadiazole-3-carboximidamide Chemical compound BrC=1C=C(C=CC1F)N(C(=N)C1=NON=C1NCC=1N=CSC1)O MTOQTNOOUHGNNT-UHFFFAOYSA-N 0.000 claims 1
- ZVMBULHWHKLVMP-UHFFFAOYSA-N N-[4-(N'-benzyl-N-hydroxycarbamimidoyl)-1,2,5-oxadiazol-3-yl]benzamide Chemical compound N=1ON=C(NC(=O)C=2C=CC=CC=2)C=1C(=NO)NCC1=CC=CC=C1 ZVMBULHWHKLVMP-UHFFFAOYSA-N 0.000 claims 1
- KTUZUPVCOJIGFT-UHFFFAOYSA-N N-[4-[N'-(3-chlorophenyl)-N-hydroxycarbamimidoyl]-1,2,5-oxadiazol-3-yl]-2-phenylacetamide Chemical compound N=1ON=C(NC(=O)CC=2C=CC=CC=2)C=1C(=NO)NC1=CC=CC(Cl)=C1 KTUZUPVCOJIGFT-UHFFFAOYSA-N 0.000 claims 1
- CGWIMBUIPUQFJS-UHFFFAOYSA-N N-[4-[N'-(3-chlorophenyl)-N-hydroxycarbamimidoyl]-1,2,5-oxadiazol-3-yl]benzamide Chemical compound N=1ON=C(NC(=O)C=2C=CC=CC=2)C=1C(=NO)NC1=CC=CC(Cl)=C1 CGWIMBUIPUQFJS-UHFFFAOYSA-N 0.000 claims 1
- SONAXYZZPNJPEB-UHFFFAOYSA-N ON(C(=N)c1nonc1NCc1ccc(CN2CCNCC2)cc1)c1ccc(F)c(Br)c1 Chemical compound ON(C(=N)c1nonc1NCc1ccc(CN2CCNCC2)cc1)c1ccc(F)c(Br)c1 SONAXYZZPNJPEB-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- XRLDSWLMHUQECH-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1CCCC1 XRLDSWLMHUQECH-UHFFFAOYSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- BXSMYXBCTAROPY-UHFFFAOYSA-N n-(3-bromo-4-fluorophenyl)-4-[(3-cyanophenyl)methylamino]-n-hydroxy-1,2,5-oxadiazole-3-carboximidamide Chemical compound C=1C=C(F)C(Br)=CC=1N(O)C(=N)C1=NON=C1NCC1=CC=CC(C#N)=C1 BXSMYXBCTAROPY-UHFFFAOYSA-N 0.000 claims 1
- XXWGOBPOIDVWQC-UHFFFAOYSA-N n-(3-bromo-4-fluorophenyl)-4-[(4-cyanophenyl)methylamino]-n-hydroxy-1,2,5-oxadiazole-3-carboximidamide Chemical compound C=1C=C(F)C(Br)=CC=1N(O)C(=N)C1=NON=C1NCC1=CC=C(C#N)C=C1 XXWGOBPOIDVWQC-UHFFFAOYSA-N 0.000 claims 1
- DFVFIQPIGWOJMP-UHFFFAOYSA-N n-(3-bromo-4-fluorophenyl)-n-hydroxy-4-(2h-tetrazol-5-ylmethylamino)-1,2,5-oxadiazole-3-carboximidamide Chemical compound C=1C=C(F)C(Br)=CC=1N(O)C(=N)C1=NON=C1NCC=1N=NNN=1 DFVFIQPIGWOJMP-UHFFFAOYSA-N 0.000 claims 1
- YNXLVVLIMVIFAG-UHFFFAOYSA-N n-(3-bromo-4-fluorophenyl)-n-hydroxy-4-(methylamino)-1,2,5-oxadiazole-3-carboximidamide Chemical compound CNC1=NON=C1C(=N)N(O)C1=CC=C(F)C(Br)=C1 YNXLVVLIMVIFAG-UHFFFAOYSA-N 0.000 claims 1
- BJDHZQFFIYGHEL-UHFFFAOYSA-N n-(3-bromo-4-fluorophenyl)-n-hydroxy-4-(pyridin-3-ylmethylamino)-1,2,5-oxadiazole-3-carboximidamide Chemical compound C=1C=C(F)C(Br)=CC=1N(O)C(=N)C1=NON=C1NCC1=CC=CN=C1 BJDHZQFFIYGHEL-UHFFFAOYSA-N 0.000 claims 1
- FSKLAERDNWODQS-UHFFFAOYSA-N n-(3-bromo-4-fluorophenyl)-n-hydroxy-4-[[4-(morpholin-4-ylmethyl)phenyl]methylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound C=1C=C(F)C(Br)=CC=1N(O)C(=N)C1=NON=C1NCC(C=C1)=CC=C1CN1CCOCC1 FSKLAERDNWODQS-UHFFFAOYSA-N 0.000 claims 1
- RSHUIOLAPCKTHD-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-4-[(3-cyanophenyl)methylamino]-n-hydroxy-1,2,5-oxadiazole-3-carboximidamide Chemical compound C=1C=C(F)C(C#N)=CC=1N(O)C(=N)C1=NON=C1NCC1=CC=CC(C#N)=C1 RSHUIOLAPCKTHD-UHFFFAOYSA-N 0.000 claims 1
- HHMPXRNDSHGYFO-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-n-hydroxy-4-(pyridin-4-ylmethylamino)-1,2,5-oxadiazole-3-carboximidamide Chemical compound C=1C=C(F)C(C#N)=CC=1N(O)C(=N)C1=NON=C1NCC1=CC=NC=C1 HHMPXRNDSHGYFO-UHFFFAOYSA-N 0.000 claims 1
- XUIBYNRHEBTKIR-UHFFFAOYSA-N n-benzyl-4-(benzylamino)-n-hydroxy-1,2,5-oxadiazole-3-carboximidamide Chemical compound N=1ON=C(NCC=2C=CC=CC=2)C=1C(=N)N(O)CC1=CC=CC=C1 XUIBYNRHEBTKIR-UHFFFAOYSA-N 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000008525 senile cataract Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Claims (38)
1. Spoj formule:
[image]
ili njegova farmaceutski prihvatljiva sol, naznačena time da:
W, X1 i X2 su nezavisno odabrani od (CRaRb)t, (CRaRb)uO(CRaRb)v, (CRaR0)uC(O)(CRaRb)v, (CRaRb)uC(O)NRc(CRaRb)v, (CRaRb)uC(O)O(CRaRb)v, (CRaRb)uC(S)(CRaRb)v, (CRaRb)uC(S)NRc(CRaRb)v, (CRaRb)uS(O)(CRaRb)v, (CRaRb)uS(O)NRc(CRaRb)v, (CRaRb)uS(O)2(CRaRb)v, (CRaRb)uS(O)2NRc(CRaRb)v, (CRaRb)uNRc(CRaRb)v i (CRaRb)uC(=NRd)NRc(CRaRb)v;
R2 predstavlja H, C1-6 alkil ili C3-7 cikloalkil;
R3a i R5a su nezavisno odabrani od C1-8 alkila, C2-8 alkenila, C2-8 alkinila, arila, cikloalkila, heteroarila i heterocikloalkila od kojih svaki može biti izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, Cy1, CN, NO2, ORel, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rh1, NRg1C(O)ORe1, C(=NR)NRg1Rh1, NRglC(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1;
R3b predstavlja aril ili heteroaril od kojih svaki može biti izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORel, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRglRh1, NRg1C(O)NRg1Rgl, NRg1Rh1, NRglC(O)Rh1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)OR ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1;
R5b predstavlja H, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil, gdje je svaki spomenuti C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rh1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)R11, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRglRh1;
Cy1 i Cy2 su nezavisno odabrani od arila, heteroarila, cikloalkila i heterocikloalkila od kojih svaki može biti izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-4 alkila, C2-4 alkenila, C2-4 alkinila, C1-4 haloalkila, CN, NO2, ORe3, SRc3, C(O)Rf3, C(O)NRg3Rh3, C(O)ORe3, OC(O)Rf3, OC(O)NRg3Rh3 NRg3Rh3, NRg3C(O)Rh3, NRg3C(O)ORg3, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRglRh1, P(Rf3)2, P(ORe3)2, P(O)Re3Rf3, P(O)ORe3ORf3, S(O)Rf3, S(O)NRg3Rh3, S(O)2Rf3 i S(O)2NRg3Rh3;
Ra i Rb su nezavisno odabrani od H, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila, heterocikloalkilalkila, CN, NO2, ORe4, SRe4, C(O)Rf4, C(O)NRg4R, C(O)ORe4, OC(O)Rf4, OC(O)NRg4Rh4, NRg4Rh4, NR94C(O)Rh4, NRg4C(O)ORe4, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf4)2, P(ORe4)2, P(O)Re4Rf4, P(O)ORe4ORf4, S(O)Rf4, S(O)NRg4Rh4, S(O)2R i S(O)2NRg4Rh4;
Rc predstavlja H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, arilalkil ili cikloalkilalkil;
Rd predstavlja H, ORd1, CN ili NO2;
Rd1 predstavlja H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, arilalkil ili cikloalkilalkil;
Re1, Re3 i Re4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, (C1-6 alkoksi)-C1-6 alkila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila i heterocikloalkilalkila;
Rf1, Rf3 i Rf4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila i heterocikloalkila;
Rg1, Rg3 i Rg4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila i cikloalkilalkila;
Rh1, Rh3 i Rh4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila i cikloalkilalkila;
ili Rgl i Rhl zajedno s atomom dušika za koji su vezani formiraju heterocikloalkilnu skupinu s 4, 5, 6 ili 7 članova; ili Rg3 i Rh3 zajedno s atomom dušika za koji su vezani formiraju heterocikloalkilnu skupinu s 4, 5, 6 ili 7 članova; ili Rg4 i Rh4 zajedno s atomom dušika za koji su vezani formiraju heterocikloalkilnu skupinu s 4, 5, 6 ili 7 članova;
Ri predstavlja H, CN ili NO2;
a predstavlja 0 ili 1;
b predstavlja 0 ili 1;
n predstavlja 0 ili 1;
p predstavlja 0 ili 1;
t predstavlja 1, 2, 3, 4, 5 ili 6;
u predstavlja 0, 1, 2, 3, 4, 5 ili 6; i
v predstavlja 0, 1, 2, 3, 4, 5 ili 6.
2. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da n predstavlja 0.
3. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da p predstavlja 1.
4. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da R50 predstavlja H.
5. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da R3b predstavlja fenil izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, Cy2, CN, NO2, ORe1, SRel, C(O)Rh1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rh1, NRg1C(O)ORe1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rh1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1.
6. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da i a i b predstavljaju 0.
7. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da a predstavlja 0.
8. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da b predstavlja 1.
9. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da R3b predstavlja heteroaril izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halogo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, Cy2, CN, NO2, ORe1, SRel, C(O)Rf1, C(O)NRglRh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rhl, NRg1C(O)NRglRh1, NRg1Rhl NRg1C(O)Rh1, NRglC(O)ORe1, P(Rf1)2, P(ORe1)2, P(O)RelRf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRglRh1, S(O)2Rf1 i S(O)2NRg1Rh1.
10. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da W predstavlja (CRaRb)t ili (CRaRb)uO(CRaRb)v.
11. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da R2 predstavlja H.
12. Spoj prema patentnom zahtjevu 11 ili njegova farmaceutski prihvatljiva sol, naznačen time da n predstavlja 0.
13. Spoj prema patentnom zahtjevu 12 ili njegova farmaceutski prihvatljiva sol, naznačen time da p predstavlja 1.
14. Spoj prema patentnom zahtjevu 13 ili njegova farmaceutski prihvatljiva sol, naznačen time da R5b predstavlja H.
15. Spoj prema patentnom zahtjevu 14 ili njegova farmaceutski prihvatljiva sol, naznačen time da W predstavlja (CRaRb)t ili (CRaRb)uO(CRaRb)v.
16. Spoj prema patentnom zahtjevu 15 ili njegova farmaceutski prihvatljiva sol, naznačen time da a predstavlja 0.
17. Spoj prema patentnom zahtjevu 16 ili njegova farmaceutski prihvatljiva sol, naznačen time da b predstavlja 0.
18. Spoj prema patentnom zahtjevu 17 ili njegova farmaceutski prihvatljiva sol, naznačen time da R3b predstavlja fenil izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRglRh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRglC(O)Rf1, NRglC(O)ORe1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rhl, S(O)2Rf1 i S(O)2NRglRh1.
19. Spoj prema patentnom zahtjevu 15 ili njegova farmaceutski prihvatljiva sol, naznačen time da b predstavlja 1.
20. Spoj prema patentnom zahtjevu 19 ili njegova farmaceutski prihvatljiva sol, naznačen time da R3b predstavlja heteroaril izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRglRh1, NRg1Rh1 NRglC(O)Rh1, NRg1C(O)ORf1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1.
21. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da i n i p predstavljaju 0.
22. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da X1 predstavlja (CRaRb)t, (CRaRb)uC(O)(CRaRb)v, (CRaRb)uC(O)NRc(CRaRb)v ili (CRaRb)uC(O)O(CRaRb)v.
23. Spoj prema patentnom zahtjevu 1 formule:
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time da:
X1 predstavlja (CRaRb)t ili (CRaRb)uC(O)(CRaRb)v;
R3b predstavlja C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil od kojih svaki može biti izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy1, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1;
R3b predstavlja aril ili heteroaril od kojih svaka može biti izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-6alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1;
R5b predstavlja H, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil, gdje je svaki spomenuti C1-8 alkil, C2-8 alkenil, C2-8 alkinil, aril, cikloalkil , heteroaril ili heterocikloalkil izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NRhg1C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2ORf1 i S(O)2NRg1Rh1;
Cy1 i Cy2 su nezavisno odabrani od arila, heteroarila, cikloalkila i heterocikloalkila od kojih svaki može biti izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-4 alkila, C2-4 alkenila, C2-4aikinila, C1-4 haloalkila, CN, NO2, ORe, SRe3, C(O)Re3, C(O)NRg3Rh3, C(O)ORe3, OC(O)Rf3, OC(O)NRg3Rh3, NRg3Rh3, NRg3C(O)Rh3, NRg3C(O)ORe3, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf3)2, P(ORe3)2, P(O)Re3Rf3, P(O)ORe3ORf3, S(O)Rf3, S(O)NRg3Rh3, S(O)2ORf3 i S(O)2NRg3Rh3;
Ra i Rb su nezavisno odabrani od H, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila, heterocikloalkilalkila, CN, NO2, ORe4, SRe4, C(O)Rf4, C(O)NRg4Rh4, C(O)ORe4, OC(O)Rf4, OC(O)NRg4Rh4, NRg4Rh4, NRg4C(O)Rh4, NRg4C(O)ORe4, C(=NRi)NRg4Rh4, NRg1C(=NRi)NRg1Rh1, P(Rf4)2, P(ORe4)2, P(O)R4Rf4, P(O)ORe4ORf4, S(O)Rf4, S(O)NRg4Rh4, S(O)2Rf4 i S(O)2NRg4Rh4;
Re1, Re3 i Re4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, (C1-6 alkoksi)-C1-6 alkila, C2-6 alkinila, arila, cikloalkila, heteroarila, helerocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila i heterocikloalkilatkila;
Rf1, Rf3 i Rf4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila i heterocikloalkila;
Rg1, Rg3 i Rg4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6alkinila, arila, cikloalkila, arilalkila i cikloalkilalkila;
Rh1, Rh3 i Rh4 su nezavisno odabrani od H, C1-6alkila, C1-6haloalkila, C2-6alkenila, C2-6 alkinila, arila, cikloalkila, arilalkila i cikloalkilalkila;
ili Rg1 i Rh1 zajedno sa atomom dušika za koji su vezani formiraju heterocikloalkilnu skupinu s 4, S, 6 ili 7 članova;
ili Rg3 i Rh3 zajedno sa atomom dušika za koji su vezani formiraju heterocikloalkilnu skupinu s 4, 5, 6 ili 7 članova ;
ili Rg4 i Rh4 zajedno sa atomom dušika za koji su vezani formiraju heterocikloalkilnu skupinu s 4, 5, 6 ili 7 članova;
Ri predstavlja H, CN ili NO2;
a predstavlja 0 ili 1;
t predstavlja 1, 2, 3, 4, 5 ili 6;
u predstavlja 0, 1, 2, 3, 4, 5 ili 6; i
v predstavlja 0, 1, 2, 3, 4, 5 ili 6.
24. Spoj prema patentnom zahtjevu 23 ili njegova farmaceutski prihvatljiva sol, naznačen time da R3a predstavlja C1-8 alkil.
25. Spoj prema patentnom zahtjevu 23 ili njegova farmaceutski prihvatljiva sol, naznačen time da R5b predstavlja H, aril ili heteroaril, gdje svaki spomenuti aril i heteroaril može biti izborno supstituiran s 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRglRh1, NRg1C(O)NRglRh1, NRglRh1, NRg1C(O)Rh1, NRglC(O)ORe1, C(=NRi)NRglRh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rfl, P(O)ORe1ORf1, S(O)Rf1, S(O)NRglRh1, S(O)2Rf1 i S(O)2NRglRh1.
26. Spoj prema patentnom zahtjevu 1, naznačen time da je odabran od:
N-benzil-4-(benzilamino)-N-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
4-[(anilinokarbonil)amino]-N-(3-klorofenil)-N-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
tert-butil {4-[({4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino)karbonil]benzil}karbamata;
4-(aminometil)-N-{4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamida;
4-{[(benzilamino)karbonil]amino}-N-(3-bromo-4-fluorofenil)-N-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}morfolin-4-karboksamida;
N-(3-bromo-4-fluorofenil)-N-hidroksi-4-(metilamino)-1,2,5-oksadiazol-3-karboksimidamida;
N/-{4-[(E,Z)-[(3-bromo4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-4-karboksamida;
tert-butil 4-{4-[({4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino)karbonil]benzil}piperazin-1-karboksilata;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazo1-3-il}-4-(piperazin-1-ilmetil)benzamida;
1-benzoil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-4-karboksamida;
N(4)-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-N(1)-fenilpiperidin-1,4-dikarboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-etilpiperidin-4-karboksamida;
4-[(benzoilamino)metil]-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-cijanofenoksi)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-fenilpiperidin-4-karboksamida;
N-(3-bromo-4-fluorofenil)-4-({4-[(1,1-dioksidotiomorfolin-4-il)metil]benzil}amino)-N-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
N-(3-bromo-4-fluorofenil)-N-hidroksi-4-{[4-(morfolin-4-ilmetil)benzil]amino}-1,2,5-oksadiazol-3-karboksimidamida;
N-(3-cijano-4-fluorofenil)-4-({4-[(1,1-dioksidotiomorfolin-4-il)metil]benzil}amino)-N-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
N-(3-bromo-4-fluorofenil)-N-hidroksi-4-[(piridin-3-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamida;
N-(3-cijano-4-fluorofenil)-N-hidroksi-4-[(piridin-4-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamida;
4-[(3-cijanobenzil)amino]-N-(3-cijano-4-fluorofenil)-N-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
N-(3-Bromo-4-fluorofenil)-N-hidroksi-4-[(1H-tetrazol-5-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamida;
N-{4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}ciklopentankarboksamida;
N-{4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metilj-1,2,5-oksadiazol-3-il}nikotinamida;
N-{4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metilj-1,2,5-oksadiazol-3-il}izonikotinamida;
N-{4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metoksibenzamida;
N-{4-[(E,Z)-[(3-klorofenil)arnino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il)-3-metoksibenzamida;
N-{4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metoksibenzamida;
2-kloro-N-{4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamida;
3-kloro-N-{4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamida;
4-kloro-N-{4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamida;
N-{4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3,3-dimetilbutanamida;
N-{4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-jodobenzamida;
N-{4-[(E,Z)-[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-cijanobenzamida;
N-{4-[(E,Z)-{[4-fluoro-3-(trifluorometil)fenil]amino}(hidroksiimino)metil]-1,2,5-oksadiazol-3-il}nikotinamida;
N-{4-[(E,Z)-{[4-fluoro-3-(trifluorometil)fenil]amino}(hidroksiimino)metil]-1,2,5-oksadiazol-3-il}izonikotinamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}nikotinamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}izonikotinamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-cijanobenzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-cijanobenzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-naftamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-naftamida;
1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-iI}piperidin-4-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-furamida;
N-{4-[(E,Z)-(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}tiofen-2-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-fenil-5-(trifluorometil)-1H-pirazol-4-karboksamida;
4-(acetilamino)-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid
tert-butil {4-[({4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino)karbonil]benzil}karbamat
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-benzotiofen-2-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,3-tiazol-4-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-benzotiofen-3-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}tiofen-3-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1H-imidazol-2-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-1,2,3-tiadiazol-5-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,2,3-tiadiazol-4-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,1-benzizoksazol-3-karboksamida;
4-(aminometil)-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamid;
N-(3-bromo-4-fluorofenil)-N'-hidroksi-4-({[(2-feniletil)amino]karbonil}amino)-1,2,5-oksadiazol-3-karboksimidamida;
N-(3-bromo-4-fluorofenil)-4-{[(ciklopentilamino)karbonil]amino}-N'-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
N-(3-bromo-4-fluorofenil)-4-({[(3-cijanofenil)amino]karbonil}amino)-N'-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-tert-butil-1-metil-1H-pirazol-5-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metoksiacetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}ciklopentankarboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}butanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metilpropanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}propanamida;
N-{4-[(E,Z)-(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}cikloheksankarboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1H-benzimidazol-5-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino]{hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-fenoksiacetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}ciklobutankarboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-metilbutanamida;
/V-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazo1-3-il}-3-piridin-3-ilpropanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}kinolin-6-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-klorofenoksi)acetamida;
N-{4-[(E,Z)-(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-bromofenoksi)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3il}-2-(4-fluorofenoksi}acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-tert-butilfenoksi)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3-klorofenoksi)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3,4-diklorofenoksi)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-naftiloksi)acetamid;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2,3-diklorofenoksi)acetamida;
N-{4-[(E,Z)-(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-klorofenoksi)-2-metilpropanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-klorofenoksi)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3-metoksifenoksi)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-metoksifenoksi)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-metoksifenoksi)acetamida;
benzil {4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazo!-3-ii}karbamata;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-1-karboksamida;
N-(3-bromo-4-fluorofenil)-4-({[(3-cijanofenil)(metil)amino]karbonil}amino)-N'-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
4-({[benzil(metil)amino]karbonil}amino)-N-(3-bromo-4-fluorofenil)-N-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-feniiacetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3-metoksifenil)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-metoksifenil)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-metoksifenil)acetamida;
N-{4-[(E,Z)-[(3-bromo4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-cijanobenzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-bromofenil)propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-bromofenil)propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-klorofenil)propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-klorofenil)
propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]1,2,5-oksadiazol-3-il)-3-(2-fiuorofenil)propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-fluorofenil)propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(2-klorofenil)propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-metilfenil)propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-(trifluorometil)fenil)propanamida;
N-{4-[(E,Z)-[(3-bromo4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-fluorofenil)propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(2-metoksifenil)propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-metoksifenil)propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-metoksifenil)propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino]hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(4-metilfenil)propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofeniI)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-[4-
(trifluorometil)fenil]propanamida;
3-[2,5-bis(trifluorometil)fenil)-N-{4-[(£>Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}propanamida;
3-[3,5-bis(trifluorometil)fenil]-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}propanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metil-3-fenilpropanamida;
2-benzil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3,3-dimetilbutanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-[4-(trifluorometil)pirimidin-2-il]piperidin-4-karboksamida;
1-benzil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-tert-butil-1H-pirazol-5-karboksamida;
2-(benziloksi)-N-{4-[(E,Z)-[{3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-(4-klorofenil)ciklopentankarboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-fenoksibenzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,4,6-triklorobenzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metoksibenzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-metoksibenzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,2-difenilacetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-(trifluorometoksi)benzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metoksibenzamida;
N-{4-[(E,Z)-(3-bromo-4-fiuorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3,4-dimetoksibenzamida;
N-(4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-nitrofenoksi)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}bifenil-4-karboksamida; N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2,6-diklorobenzil)-1,3-tiazol-4-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,6-dimetoksibenzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-nitrobenzamida;
5-bromo-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}nikotinamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3,3-dimetilbutanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino]{hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(2-tienil)acetamida:
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino]{hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-fenilbutanamida;
N-{4-[{E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,2-dimetilpropanamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-(morfolin-4-ilmetil)benzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-[(1,1-dioksidotiomorfolin-4-il)metil]benzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-(fenilacetil)piperidin-4-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-(metilsulfonil)piperidin-4-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-piridin-4-il-1,3-tiazol-4-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-nitrobenzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-ii}-3-nitrobenzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-izopropilpiperidin-4-karboksamida;
tert-butil 4-{4-[({4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil)]-1,2,5-oksadiazol-3-il}amino)karbonil]-1,3-tiazol-2-il}piperidin-1-karboksilata;
N-{4-[(E,Z)-[(3-bromo-4-fiuorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-ii}-2-fenil-1,3-tiazol-4-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-metil-1,3-tiazol-4-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-piperidin-4-il-1,3-tiazol-4-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-cijanofenoksi)acetamida;
tert-butil 3-[({4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}amino)karbonil]piperidin-1-karboksilata;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino]hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-3-(3-nitrofenil)propanamid;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(3-nitrofenoksi)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(4-nitrofenoksi)acetamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-3-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-2-piridin-3-il-1,3-tiazol-5-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-1,3-tiazol-5-karboksamida;
2-amino-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,3-tiazol-4-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metil-2-pirazin-2-il-1,3-tiazol-5-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazo!-3-il}-4-metil-2-[4-(trifluorometil)fenil]-1,3-tiazol-5-karboksamida;
N-{4-[(E,Z)-[(3-bromo4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2,4-dimetil-1,3-tiazol-5-karboksamida;
1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}pirolidin-2-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fiuorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1.5-dimetil-1H-pirazoi-3-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-5-kloro-1-metil-1H-pirazol-4-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1,3-dimetil-1H-pirazol-5-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-metil-1H-imidazol-2-karboksamida;
4-[(acetilamino)metil]-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-metilpiperidin-4-karboksamida;
1-acetil-N-{4-[(E,Z)-(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperidin-3-karboksamida;
1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazoi-3-il}-4-metilpiperidin-4-karboksamida;
1-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino)(hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-fenilpiperidin-4-karboksamida;
4-(benzilamino)-N-(3-bromo-4-fluorofenil)-N'-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-1-etilpiperidin-3-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-4-etilpiperazin-1-karboksamida;
4-acetil-N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}piperazin-1-karboksamida;
N-{4-[(E,Z)-[(3-bromo-4-fluorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-(1-etilpiperidin-4-il)-1,3-tiazol-4-karboksamida;
N-(3-bromo-4-fluorofenil)-N-hidroksi-4-[(1,3-tiazol-4-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamida;
N-(3-bromo-4-fluorofenil)-4-[(4-cijanobenzil)amino]-N-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
N-(3-bromo-4-fluorofenil)-N'-hidroksi-4-{[(1-metilpiperidin-4-il)metil]amino}-1,2,5-oksadiazol-3-karboksimidamida;
N-(3-bromo-4-fluorofenil)-N-hidroksi-4-{[4-(piperazin-1-ilmetil)benzil]amino}-1,2,5-oksadiazol-3-karboksimidamida;
N-(3-bromo-4-fluorofenil)-4-({4-[(4-etilpiperazin-1-il)metil]benzil}amino)-N'-hidroksi-1,2,5-oksadiazol-3-karboksimidamida;
N-(3-bromo-4-fluorofenil)-N'-hidroksi-4-[(piridin-4-ilmetil)amino]-1,2,5-oksadiazol-3-karboksimidamida; i
N-(3-bromo-4-fluorofenil)-4-[(3-cijanobenzil)amino]-N-hidroksi-1,2,5-oksadiazol-3-karboksimidamida
ili njihove farmaceutski prihvatljive soli.
27. Spoj prema patentnom zahtjevu 1, naznačen time da je odabran od:
N-{4-[[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}-2-fenilacetamida;
N-{4-[[(3-klorofenil)amino](hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamida; i
N-{4-[(benzilamino)(hidroksiimino)metil]-1,2,5-oksadiazol-3-il}benzamida;
ili njihove farmaceutski prihvatljive soli.
28. Farmaceutski sastav, naznačen time da sadrži spoj prema bilo kojem patentnom zahtjevu od 1 do 27 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljivi nosač.
29. Metoda za modulaciju aktivnosti indolamin 2,3-dioksigenaze, naznačena time da obuhvaća kontakt spomenute indolamin 2,3-dioksigenaze ex vivo sa spojem prema bilo kojem patentnom zahtjevu od 1 do 27 ili s njegovom farmaceutski prihvatljivom soli ili farmaceutskim sastavom prema patentnom zahtjevu 28.
30. Metoda prema patentnom zahtjevu 29, naznačena time da navedena modulacija predstavlja inhibiciju.
31. Spoj prema bilo kojem patentnom zahtjevu od 1 do 27 ili njegova farmaceutski prihvatljiva sol ili farmaceutski sastav prema patentnom zahtjevu 28, naznačen time da se koristi u inhibiciji imunosupresije kod pacijenta.
32. Spoj prema bilo kojem patentnom zahtjevu od 1 do 27 ili njegova farmaceutski prihvatljiva sol ili farmaceutski sastav prema patentnom zahtjevu 28, naznačen time da se koristi u liječenju raka, virusne infekcije, depresije, neurodegenerativnog poremećaja, traume, staračke katarakte, odbacivanja transplantiranog organa ili autoimune bolesti pacijenta.
33. Spoj, sol ili sastav prema patentnom zahtjevu 32, naznačen time da se koristi za liječenje raka kod pacijenta.
34. Spoj, sol ili sastav prema patentnom zahtjevu 32, naznačen time da je spomenuti rak odabran od raka kolona, raka gušterače, raka dojke, raka prostate, raka pluća, raka mozga, raka jajnika, raka vrata materice, raka testisa, raka bubrega, raka glave i vrata, limfoma, leukemije i melanoma.
35. Spoj, sol ili sastav prema patentnom zahtjevu 32, naznačen time da se koristi u kombinaciji s cjepivom protiv raka, protuvirusnim sredstvom, kemoterapeutikom, imunosupresantom, zračenjem, cjepivom protiv tumora, cjepivom protiv virusa, terapijom citokinima ili inhibitorom tirozin kinaze.
36. Spoj, sol ili sastav prema patentnom zahtjevu 35, naznačen time da spomenuta terapija citokinima predstavlja terapiju s IL-2.
37. Spoj, sol ili sastav prema patentnom zahtjevu 35, naznačen time da spomenuti kemoterapeutik predstavlja citotoksični agens.
38. Spoj, sol ili sastav prema patentnom zahtjevu 32, naznačen time da se koristi u kombinaciji s anti-CTLA-4 antitijelom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67950705P | 2005-05-10 | 2005-05-10 | |
PCT/US2006/017983 WO2006122150A1 (en) | 2005-05-10 | 2006-05-09 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20130220T1 true HRP20130220T1 (hr) | 2013-04-30 |
Family
ID=37396891
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20130220TT HRP20130220T1 (hr) | 2005-05-10 | 2013-03-13 | Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih |
HRP20160537TT HRP20160537T1 (hr) | 2005-05-10 | 2016-05-19 | Modulatori indolamina 2,3-dioksigenaze i metode za upotrebu istih |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160537TT HRP20160537T1 (hr) | 2005-05-10 | 2016-05-19 | Modulatori indolamina 2,3-dioksigenaze i metode za upotrebu istih |
Country Status (33)
Country | Link |
---|---|
US (6) | US8034953B2 (hr) |
EP (3) | EP1879573B1 (hr) |
JP (2) | JP4990270B2 (hr) |
KR (2) | KR101562549B1 (hr) |
CN (2) | CN103130735B (hr) |
AR (1) | AR054271A1 (hr) |
AU (1) | AU2006244068B9 (hr) |
BR (2) | BR122020016659B8 (hr) |
CA (1) | CA2606783C (hr) |
CR (1) | CR9485A (hr) |
CY (2) | CY1113989T1 (hr) |
DK (2) | DK2559690T3 (hr) |
EA (1) | EA026785B1 (hr) |
ES (2) | ES2401482T3 (hr) |
GE (1) | GEP20217221B (hr) |
HK (2) | HK1117392A1 (hr) |
HR (2) | HRP20130220T1 (hr) |
HU (1) | HUE029214T2 (hr) |
IL (2) | IL186957A (hr) |
ME (1) | ME02461B (hr) |
MX (1) | MX2007013977A (hr) |
MY (1) | MY153424A (hr) |
NO (2) | NO340487B1 (hr) |
NZ (1) | NZ562919A (hr) |
PL (2) | PL1879573T3 (hr) |
PT (2) | PT2559690T (hr) |
RS (2) | RS52711B (hr) |
SG (3) | SG10201809390QA (hr) |
SI (2) | SI1879573T1 (hr) |
TW (1) | TWI377060B (hr) |
UA (1) | UA99897C2 (hr) |
WO (1) | WO2006122150A1 (hr) |
ZA (1) | ZA200709698B (hr) |
Families Citing this family (241)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1468102B1 (en) * | 2002-01-22 | 2009-05-27 | Biomatera Inc. | Method of drying biodegradable polymers |
EP1846401B1 (en) * | 2005-02-04 | 2008-06-18 | CTG Pharma S.r.l. | New 4-aminoquinoline derivatives as antimalarials |
AR052289A1 (es) | 2005-02-14 | 2007-03-07 | Wyeth Corp | Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f y sus usos |
SI1879573T1 (sl) * | 2005-05-10 | 2013-04-30 | Incyte Corporation Experimental Station | Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te |
GB0512091D0 (en) * | 2005-06-14 | 2005-07-20 | Novartis Ag | Organic compounds |
DE102005053947A1 (de) * | 2005-11-11 | 2007-05-16 | Univ Ernst Moritz Arndt | Neue Arzneimittel |
ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
US20070203140A1 (en) * | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
EP2086970B1 (en) * | 2006-08-24 | 2014-02-26 | Novartis AG | 2-(pyrazin-2-yl)-thiazole and 2-(1h pyrazol-3-yl)-thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロサイクル |
CL2007002650A1 (es) * | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
US20080146624A1 (en) * | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
BRPI0718509A2 (pt) | 2006-09-22 | 2015-09-29 | Novartis Ag | compostos orgânicos heterocíclicos |
WO2008058178A1 (en) * | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
CN101595105B (zh) | 2006-12-20 | 2013-01-23 | 诺瓦提斯公司 | 作为scd抑制剂的2-取代的5元杂环化合物 |
EP2137168B1 (en) * | 2007-03-16 | 2016-09-14 | Lankenau Institute for Medical Research | Novel ido inhibitors and methods of use thereof |
US20090170842A1 (en) * | 2007-11-14 | 2009-07-02 | University Of Kansas | Brca1-based breast or ovarian cancer prevention agents and methods of use |
CN101932325B (zh) * | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
US20090253706A1 (en) * | 2008-04-03 | 2009-10-08 | Muller Alexander J | Methods and Compositions for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases |
EP3320912B1 (en) | 2008-04-17 | 2021-03-31 | IO BIOTECH ApS | Indoleamine 2, 3-dioxygenase based immunotherapy |
NO2824100T3 (hr) | 2008-07-08 | 2018-07-21 | ||
AU2010297635B2 (en) | 2009-09-25 | 2015-05-07 | Bayer Cropscience Aktiengesellschaft | N-(1,2,5-oxadiazol-3-yl) benzamides and the use thereof as herbicides |
JP2012041325A (ja) * | 2010-08-23 | 2012-03-01 | Bayer Cropscience Ag | オキサジアゾリノン誘導体およびその有害生物の防除用途 |
PL2654758T3 (pl) * | 2010-12-22 | 2017-10-31 | Idogen Ab | Kompozycja zawierająca co najmniej dwa związki, która indukuje 2,3-dioksygenazę indolaminy (IDO) do leczenia zaburzenia autoimmunologicznego lub immunologicznego odrzucenia narządów |
NO2694640T3 (hr) * | 2011-04-15 | 2018-03-17 | ||
EP2780339A1 (en) | 2011-11-16 | 2014-09-24 | Basf Se | Substituted 1,2,5-oxadiazole compounds and their use as herbicides ii |
CN104039780A (zh) * | 2011-11-18 | 2014-09-10 | 巴斯夫欧洲公司 | 取代的1,2,5-噁二唑化合物及其作为除草剂的用途iii |
KR101229365B1 (ko) * | 2012-07-02 | 2013-02-18 | 대한민국 | 〔z〕n〔3〔2,4디플루오로페닐아미노〕1〔4나이트로페닐〕3옥소프로프1엔2일〕2메톡시벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환 예방 및 치료용 약학적 조성물 |
US10034939B2 (en) | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
JP6327754B2 (ja) | 2013-06-21 | 2018-05-23 | クミアイ化学工業株式会社 | 2−アミノ−2−ヒドロキシイミノ−n−アルコキシアセトイミドイルシアニドの製造方法およびその製造中間体 |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
RU2536041C1 (ru) * | 2013-10-11 | 2014-12-20 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) | 3,3'-бис(фтординитрометил-onn-азокси)-4,4'-дифуразаниловый эфир и способ его получения |
ME03792B (me) * | 2013-11-08 | 2021-04-20 | Incyte Holdings Corp | Postupak sinteze inhibitora indolamin 2,3-dioksigenaze |
CN103570727B (zh) | 2013-11-12 | 2015-08-19 | 复旦大学 | 一种n-苄基色胺酮衍生物及其制备方法和应用 |
SG11201605097SA (en) | 2013-12-24 | 2016-07-28 | Bristol Myers Squibb Co | Tricyclic compounds as anticancer agents |
ES2755395T3 (es) | 2014-06-06 | 2020-04-22 | Bristol Myers Squibb Co | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos |
MX2016015610A (es) * | 2014-06-06 | 2017-07-13 | Flexus Biosciences Inc | Agentes inmunorreguladores. |
GB201414730D0 (en) | 2014-08-19 | 2014-10-01 | Tpp Global Dev Ltd | Pharmaceutical compound |
WO2016040458A2 (en) * | 2014-09-09 | 2016-03-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Pet probes of radiofluorinated carboximidamides for ido-targeted imaging |
CN105481789B (zh) * | 2014-09-15 | 2020-05-19 | 中国科学院上海有机化学研究所 | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 |
UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
EP3215141A4 (en) | 2014-11-05 | 2018-06-06 | Flexus Biosciences, Inc. | Immunoregulatory agents |
UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
US10100129B2 (en) | 2014-11-21 | 2018-10-16 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
US10525035B2 (en) | 2014-12-18 | 2020-01-07 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
TW201630907A (zh) | 2014-12-22 | 2016-09-01 | 必治妥美雅史谷比公司 | TGFβR拮抗劑 |
AU2015369683B2 (en) | 2014-12-23 | 2020-12-10 | Bristol-Myers Squibb Company | Antibodies to TIGIT |
WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
US9884868B2 (en) | 2015-03-02 | 2018-02-06 | Rigel Pharmaceuticals, Inc. | TGF-beta inhibitors |
BR112017020999A2 (pt) | 2015-04-03 | 2018-07-03 | Bristol-Myers Squibb Company | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer |
TW201642897A (zh) | 2015-04-08 | 2016-12-16 | F 星生物科技有限公司 | Her2結合劑治療 |
LT3283527T (lt) | 2015-04-13 | 2021-03-25 | Five Prime Therapeutics, Inc. | Kompleksinė terapija vėžio gydymui |
JP6801159B2 (ja) | 2015-04-21 | 2020-12-16 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | イミダゾイソインドール誘導体、その製造方法及びその医薬用途 |
WO2016183114A1 (en) | 2015-05-11 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
US10174024B2 (en) | 2015-05-12 | 2019-01-08 | Bristol-Myers Squibb Company | 5H-pyrido[3,2-B]indole compounds as anticancer agents |
US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
EP3294324A1 (en) | 2015-05-13 | 2018-03-21 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
SG10202008304TA (en) | 2015-05-29 | 2020-10-29 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
JP2018526977A (ja) | 2015-06-29 | 2018-09-20 | ザ ロックフェラー ユニヴァーシティ | アゴニスト活性が増強されたcd40に対する抗体 |
KR20180022988A (ko) * | 2015-07-02 | 2018-03-06 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 인돌아민 2,3-디옥시게나제의 억제제 |
GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
CA2992238A1 (en) | 2015-07-14 | 2017-01-19 | Kyowa Hakko Kirin Co., Ltd. | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody |
US10786547B2 (en) | 2015-07-16 | 2020-09-29 | Biokine Therapeutics Ltd. | Compositions, articles of manufacture and methods for treating cancer |
NZ736978A (en) | 2015-07-24 | 2019-06-28 | Newlink Genetics Corp | Salts and prodrugs of 1-methyl-d-tryptophan |
KR20180034548A (ko) | 2015-07-28 | 2018-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | Tgf 베타 수용체 길항제 |
WO2017035118A1 (en) | 2015-08-25 | 2017-03-02 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
CN106565696B (zh) * | 2015-10-09 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | 噁二唑类衍生物、其制备方法及其在医药上的应用 |
PE20181300A1 (es) | 2015-11-02 | 2018-08-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer |
US10894830B2 (en) | 2015-11-03 | 2021-01-19 | Janssen Biotech, Inc. | Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses |
MX2018005600A (es) | 2015-11-04 | 2018-11-09 | Incyte Corp | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. |
SG11201803817PA (en) | 2015-11-19 | 2018-06-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
CA3004794A1 (en) | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
EP3322713B1 (en) | 2015-12-03 | 2021-01-20 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
EP3389783A4 (en) | 2015-12-15 | 2019-05-15 | Merck Sharp & Dohme Corp. | NOVEL COMPOUNDS THAN INDOLAMINE-2,3-DIOXYGENASE INHIBITORS |
EP3390406A1 (en) | 2015-12-15 | 2018-10-24 | Bristol-Myers Squibb Company | Cxcr4 receptor antagonists |
CN106883193B (zh) * | 2015-12-15 | 2021-10-15 | 上海翰森生物医药科技有限公司 | 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用 |
CN106883194A (zh) * | 2015-12-16 | 2017-06-23 | 江苏恒瑞医药股份有限公司 | 噁二唑类衍生物、其制备方法及其在医药上的应用 |
US9624185B1 (en) * | 2016-01-20 | 2017-04-18 | Yong Xu | Method for preparing IDO inhibitor epacadostat |
CN105646389B (zh) * | 2016-01-28 | 2019-06-28 | 中国科学院上海有机化学研究所 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途 |
US20190031665A1 (en) | 2016-02-02 | 2019-01-31 | Emcure Pharmaceuticals Limited | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer |
CN107033097B (zh) * | 2016-02-04 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | 噁二唑类衍生物、其制备方法及其在医药上的应用 |
WO2017140272A1 (zh) * | 2016-02-19 | 2017-08-24 | 正大天晴药业集团股份有限公司 | 作为免疫调节剂的三并环化合物 |
WO2017149469A1 (en) | 2016-03-03 | 2017-09-08 | Emcure Pharmaceuticals Limited | Heterocyclic compounds useful as ido and/or tdo modulators |
BR112018067368A2 (pt) | 2016-03-04 | 2019-01-15 | Bristol-Myers Squibb Company | terapia de combinação com anticorpos anti-cd73 |
CN107176933B (zh) * | 2016-03-09 | 2020-10-09 | 中国科学院上海有机化学研究所 | 一种含氮烷基化和芳基化亚砜亚胺的吲哚胺-2,3-双加氧酶抑制剂 |
RU2018137389A (ru) | 2016-04-07 | 2020-05-12 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Гетероциклические амиды, полезные в качестве модуляторов |
MX2018012333A (es) | 2016-04-07 | 2019-03-07 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas utiles como moduladores de proteinas. |
WO2017184619A2 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
CN107304191B (zh) * | 2016-04-20 | 2023-09-29 | 上海翰森生物医药科技有限公司 | 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用 |
WO2017181849A1 (zh) * | 2016-04-20 | 2017-10-26 | 江苏豪森药业集团有限公司 | 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用 |
JP2019516687A (ja) | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法 |
WO2017192811A1 (en) * | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
JP2019516682A (ja) | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法 |
JP2019519485A (ja) | 2016-05-04 | 2019-07-11 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法 |
EP3452452A4 (en) * | 2016-05-04 | 2019-10-30 | Bristol-Myers Squibb Company | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE |
AR108586A1 (es) * | 2016-06-10 | 2018-09-05 | Lilly Co Eli | Compuestos de 2,3-dihidro-1h-indol |
MY200602A (en) | 2016-07-14 | 2024-01-04 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
CN109789135A (zh) | 2016-07-20 | 2019-05-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为perk抑制剂的异喹啉衍生物 |
US20190292179A1 (en) | 2016-07-21 | 2019-09-26 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
BR112019001980A2 (pt) * | 2016-08-02 | 2019-05-07 | Shandong Luye Pharmaceutical Co., Ltd. | inibidor de ido1 e método de preparação e aplicação do mesmo |
WO2018039430A1 (en) * | 2016-08-24 | 2018-03-01 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Radiofluorinated carboximidamides as ido targeting pet tracer for cancer imaging |
US11351164B2 (en) | 2016-08-26 | 2022-06-07 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2018044663A1 (en) * | 2016-08-29 | 2018-03-08 | Merck Sharp & Dohme Corp. | Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
WO2018053529A1 (en) | 2016-09-19 | 2018-03-22 | University Of South Florida | Method of targeting oncolytic viruses to tumors |
CN109952300B (zh) | 2016-09-24 | 2022-01-18 | 百济神州有限公司 | 5或8-取代的咪唑并[1,5-a]吡啶 |
CN107954999B (zh) * | 2016-10-17 | 2023-01-24 | 上海医药集团股份有限公司 | 含噁二唑环化合物、制备方法、中间体、组合物及应用 |
UY37466A (es) | 2016-11-03 | 2018-01-31 | Phenex Discovery Verwaltungs Gmbh | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa |
US11168078B2 (en) | 2016-11-28 | 2021-11-09 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase |
CN106883224B (zh) * | 2017-01-03 | 2019-10-22 | 中国药科大学 | 苯并含氮杂环类吲哚胺-2,3-双加氧酶1抑制剂及其用途 |
CN106866648B (zh) * | 2017-01-03 | 2019-10-22 | 中国药科大学 | 邻苯二甲酰亚胺类吲哚胺-2,3-双加氧酶1抑制剂及其用途 |
WO2018132279A1 (en) | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
WO2018136437A2 (en) | 2017-01-17 | 2018-07-26 | Tesaro, Inc. | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
CN106866571B (zh) * | 2017-01-20 | 2018-06-29 | 中国药科大学 | 杂环脲类化合物及其药物组合物和应用 |
WO2018156443A1 (en) * | 2017-02-24 | 2018-08-30 | Merck Sharp & Dohme Corp. | Novel substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
CN106967004B (zh) * | 2017-03-29 | 2019-09-17 | 中国药科大学 | 含脲基的ido1和ido2双重抑制剂、其制法及其医药用途 |
KR20190133171A (ko) * | 2017-03-29 | 2019-12-02 | 머크 샤프 앤드 돔 코포레이션 | 인돌아민 2,3-디옥시게나제 (ido) 억제제로서의 신규 치환된 n'-히드록시카르밤이미도일-1,2,5-옥사디아졸 화합물 |
US20200031944A1 (en) | 2017-03-31 | 2020-01-30 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
CN108689958B (zh) * | 2017-04-05 | 2021-09-17 | 南京华威医药科技集团有限公司 | 一种含有肼基的吲哚胺2,3-双加氧化酶抑制剂 |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
CA3059939A1 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
US11046679B2 (en) | 2017-04-24 | 2021-06-29 | Nanjing Transthera Biosciences Co. Ltd. | Indoleamine 2,3-dioxygenase inhibitor and application |
CN114920710A (zh) * | 2017-04-27 | 2022-08-19 | 鲁南制药集团股份有限公司 | 亚氨脲衍生物 |
AU2018258661A1 (en) | 2017-04-28 | 2019-10-17 | Five Prime Therapeutics, Inc. | Methods of treatment with CD80 extracellular domain polypeptides |
US11066392B2 (en) | 2017-05-12 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
CN109081818B (zh) * | 2017-06-14 | 2022-04-22 | 南京华威医药科技集团有限公司 | 新型吲哚胺2,3-双加氧化酶抑制剂 |
CN109111438B (zh) * | 2017-06-26 | 2021-11-02 | 正大天晴药业集团股份有限公司 | 用于ido抑制剂的脒类化合物 |
BR112019027259A2 (pt) | 2017-06-30 | 2020-07-14 | Bristol-Myers Squibb Company | formas amorfas e cristalinas de inibidores da ido |
WO2019011170A1 (zh) * | 2017-07-14 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | 噁二唑类衍生物、其制备方法及其在医药上的应用 |
WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
CN110997691B (zh) | 2017-07-28 | 2023-11-07 | 百时美施贵宝公司 | 作为抗癌剂的环二核苷酸 |
JP7269917B2 (ja) | 2017-08-17 | 2023-05-09 | イケナ オンコロジー, インコーポレイテッド | Ahr阻害剤およびその使用 |
ES2904317T3 (es) | 2017-08-31 | 2022-04-04 | Bristol Myers Squibb Co | Dinucleótidos cíclicos como agentes anticancerosos |
US20200237860A1 (en) | 2017-08-31 | 2020-07-30 | Multimmune Gmbh | Hsp70 based combination therapy |
CN111032672A (zh) | 2017-08-31 | 2020-04-17 | 百时美施贵宝公司 | 作为抗癌剂的环二核苷酸 |
JP7209697B2 (ja) | 2017-08-31 | 2023-01-20 | ブリストル-マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
EP3677581A4 (en) * | 2017-09-01 | 2021-05-05 | Nanjing Transthera Biosciences Co. Ltd. | DEUTERATED INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND USE OF IT |
CN108863976B (zh) * | 2017-09-11 | 2022-09-16 | 郑州泰基鸿诺医药股份有限公司 | 用作ido调节剂的化合物及其应用 |
EP4176876A1 (en) | 2017-09-14 | 2023-05-10 | Lankenau Institute for Medical Research | Methods and compositions for the treatment of cancer |
CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
US11111232B2 (en) | 2017-10-09 | 2021-09-07 | Merck Sharp & Dohme Corp. | Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
US11203592B2 (en) | 2017-10-09 | 2021-12-21 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019074747A1 (en) * | 2017-10-09 | 2019-04-18 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
CN111344297B (zh) | 2017-10-10 | 2023-10-20 | 百时美施贵宝公司 | 作为抗癌剂的环二核苷酸 |
EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
WO2019079261A1 (en) | 2017-10-16 | 2019-04-25 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
CN109678813A (zh) * | 2017-10-18 | 2019-04-26 | 中国科学院上海有机化学研究所 | 吲哚胺-2,3-双加氧酶抑制剂盐及其制备方法 |
EP3704159A1 (en) | 2017-11-01 | 2020-09-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
CN109748911B (zh) * | 2017-11-06 | 2022-03-11 | 中国药科大学 | 一种含三氮唑的ido抑制剂、其制备方法及其医药用途 |
US11166959B2 (en) | 2017-11-06 | 2021-11-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as HPK1 inhibitors |
CN107987031A (zh) * | 2017-12-01 | 2018-05-04 | 华东理工大学 | 一种靶向吲哚胺-2,3-双加氧酶1氮芥类抑制剂及其制备方法和应用 |
WO2019115586A1 (en) | 2017-12-12 | 2019-06-20 | Phenex Discovery Verwaltungs-GmbH | Oxalamides as modulators of indoleamine 2,3-dioxygenase |
CN108003111A (zh) * | 2017-12-14 | 2018-05-08 | 华东理工大学 | 一种hdac1和ido1双靶点抑制剂及其制备方法和应用 |
CN109942565B (zh) * | 2017-12-20 | 2021-03-26 | 海创药业股份有限公司 | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途 |
KR20200103761A (ko) | 2017-12-27 | 2020-09-02 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd40 항체 및 그의 용도 |
US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
CA3084829A1 (en) | 2018-01-05 | 2019-07-11 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and ido expression to potentiate immunotherapy |
CN111886255A (zh) | 2018-01-12 | 2020-11-03 | 百时美施贵宝公司 | 抗tim3抗体及其用途 |
CN110054622B (zh) * | 2018-01-18 | 2021-02-23 | 四川科伦博泰生物医药股份有限公司 | 噁二唑类衍生物、其制备方法及其在医药上的应用 |
CN108586378B (zh) | 2018-01-22 | 2020-06-19 | 南京华威医药科技集团有限公司 | 吲哚胺2,3-双加氧化酶抑制剂及其制备方法和用途 |
CN110092750B (zh) | 2018-01-29 | 2023-07-21 | 北京诺诚健华医药科技有限公司 | 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用 |
US10519187B2 (en) | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
CN110156674A (zh) * | 2018-02-13 | 2019-08-23 | 中国科学院上海有机化学研究所 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
CN111801341B (zh) | 2018-03-08 | 2023-10-24 | 百时美施贵宝公司 | 作为抗癌剂的环二核苷酸 |
CN111971304A (zh) | 2018-03-21 | 2020-11-20 | 戊瑞治疗有限公司 | 在酸性pH结合至VISTA的抗体 |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
US20210122757A1 (en) | 2018-03-29 | 2021-04-29 | Phenex Discovery Verwaltungs-GmbH | Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase |
KR20200142542A (ko) | 2018-04-12 | 2020-12-22 | 브리스톨-마이어스 스큅 컴퍼니 | Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법 |
US20190314324A1 (en) | 2018-04-13 | 2019-10-17 | The University Of Chicago | Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy |
AU2019255196A1 (en) | 2018-04-16 | 2020-11-12 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
WO2019206800A1 (en) | 2018-04-24 | 2019-10-31 | Phenex Discovery Verwaltungs-GmbH | Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase |
US20230339891A1 (en) | 2018-05-03 | 2023-10-26 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
CN110526898A (zh) | 2018-05-25 | 2019-12-03 | 北京诺诚健华医药科技有限公司 | 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用 |
GB201809050D0 (en) | 2018-06-01 | 2018-07-18 | E Therapeutics Plc | Modulators of tryptophan catabolism |
WO2020006018A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
SG11202012973RA (en) | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Naphthyridinone compounds useful as t cell activators |
MX2021000009A (es) | 2018-07-09 | 2021-03-09 | Five Prime Therapeutics Inc | Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4). |
PE20210687A1 (es) | 2018-07-11 | 2021-04-08 | Bristol Myers Squibb Co | Anticuerpos de union a vista a ph acido |
WO2020018670A1 (en) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
US20210355113A1 (en) | 2018-07-23 | 2021-11-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
EP3863722A2 (en) | 2018-10-10 | 2021-08-18 | Tilos Theapeutics, Inc. | Anti-lap antibody variants and uses thereof |
TW202033555A (zh) | 2018-11-16 | 2020-09-16 | 美商必治妥美雅史谷比公司 | 抗nkg2a抗體及其用途 |
CN111689952A (zh) * | 2019-03-14 | 2020-09-22 | 复旦大学 | 含硫代四元环结构的2,3-双加氧酶抑制剂及其制备方法和用途 |
CN111909107B (zh) * | 2019-05-10 | 2023-02-03 | 药康众拓(江苏)医药科技有限公司 | Ido/hdac双重抑制剂及其药物组合物和应用 |
WO2020231713A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2020231766A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
CN111943906B (zh) * | 2019-05-14 | 2023-12-15 | 中国医学科学院药物研究所 | 脒类衍生物、及其制法和药物组合物与用途 |
EP3969452A1 (en) | 2019-05-16 | 2022-03-23 | Stingthera, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
CN114302875A (zh) | 2019-05-16 | 2022-04-08 | 斯汀塞拉股份有限公司 | 氧代吖啶基乙酸衍生物及使用方法 |
CN112062732B (zh) * | 2019-06-10 | 2023-10-24 | 鲁南制药集团股份有限公司 | 一种ido抑制剂及其组合物、制备方法和用途 |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
US20220306630A1 (en) | 2019-08-06 | 2022-09-29 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
JP2022548292A (ja) | 2019-09-19 | 2022-11-17 | ブリストル-マイヤーズ スクイブ カンパニー | 酸性pHでVISTAと結合する抗体 |
MX2022005839A (es) | 2019-11-19 | 2022-06-09 | Bristol Myers Squibb Co | Compuestos utiles como inhibidores de la proteina helios. |
IL293357A (en) | 2019-11-26 | 2022-07-01 | Bristol Myers Squibb Co | Salts/crystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
JP2023502531A (ja) | 2019-11-26 | 2023-01-24 | イケナ オンコロジー, インコーポレイテッド | 多形カルバゾール誘導体およびその使用 |
IL294269A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substitute quinolinyl piperazine compounds are useful as t-cell activators |
CA3162979A1 (en) | 2019-12-23 | 2021-07-01 | Upender Velaparthi | Substituted piperazine derivatives useful as t cell activators |
US20230094758A1 (en) | 2019-12-23 | 2023-03-30 | Bristol-Myers Squibb Company | Substituted quinazolinyl compounds useful as t cell activators |
CN114846015A (zh) | 2019-12-23 | 2022-08-02 | 百时美施贵宝公司 | 用作t细胞激活剂的经取代的杂芳基化合物 |
AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
CN111138425A (zh) * | 2020-01-06 | 2020-05-12 | 中国药科大学 | 三氮唑类衍生物及其制备方法与用途 |
AU2021206618A1 (en) | 2020-01-06 | 2022-08-18 | Hifibio, Inc. | Anti-TNFR2 antibody and uses thereof |
BR112022013494A2 (pt) | 2020-01-07 | 2022-09-13 | Hifibio Hk Ltd | Anticorpo anti-galectina-9 e usos do mesmo |
EP4090663A1 (en) | 2020-01-15 | 2022-11-23 | Blueprint Medicines Corporation | Map4k1 inhibitors |
JP2023516459A (ja) | 2020-03-09 | 2023-04-19 | ブリストル-マイヤーズ スクイブ カンパニー | 増強されたアゴニスト活性を有するcd40に対する抗体 |
TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
US20230272056A1 (en) | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
WO2022033419A2 (en) | 2020-08-10 | 2022-02-17 | Shanghai Xbh Biotechnology Co., Ltd. | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
US20230416382A1 (en) | 2020-10-14 | 2023-12-28 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
AU2021400725A1 (en) | 2020-12-16 | 2023-08-03 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
US20240109899A1 (en) | 2021-02-04 | 2024-04-04 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
AU2022221124A1 (en) | 2021-02-12 | 2023-08-03 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
CN113105366B (zh) * | 2021-03-04 | 2022-05-24 | 中国药科大学 | 一类含苯基羟肟结构衍生物及其制法与用途 |
WO2022192145A1 (en) | 2021-03-08 | 2022-09-15 | Blueprint Medicines Corporation | Map4k1 inhibitors |
US11918582B2 (en) | 2021-03-15 | 2024-03-05 | Rapt Therapeutics, Inc. | Pyrazole pyrimidine compounds and uses thereof |
JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型cdcp1に対する抗体およびその使用 |
AU2022253450A1 (en) | 2021-04-05 | 2023-11-16 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
WO2022216644A1 (en) | 2021-04-06 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds |
EP4370523A1 (en) | 2021-07-14 | 2024-05-22 | Blueprint Medicines Corporation | Heterocyclic compounds as map4k1 inhibitors |
CN117940406A (zh) | 2021-07-15 | 2024-04-26 | 缆图药品公司 | Map4k1抑制剂 |
WO2023122772A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
WO2023122778A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Pyridazinone derivatives useful as t cell activators |
WO2023122777A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
WO2023150186A1 (en) | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
WO2024036100A1 (en) | 2022-08-08 | 2024-02-15 | Bristol-Myers Squibb Company | Substituted tetrazolyl compounds useful as t cell activators |
WO2024036101A1 (en) | 2022-08-09 | 2024-02-15 | Bristol-Myers Squibb Company | Tertiary amine substituted bicyclic compounds useful as t cell activators |
WO2024033458A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033388A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3236855A (en) | 1964-01-17 | 1966-02-22 | Merck & Co Inc | Certain n-phenyl(thiazole-hydroxamidine) compounds and their preparation |
US3354174A (en) | 1964-02-19 | 1967-11-21 | Sterling Drug Inc | 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines |
DE1453353A1 (de) | 1964-02-20 | 1970-01-15 | Nottmeyer Maschf Heinrich | Maschine zum Einpressen von Duebeln in eine vorgebohrte Platte oder dergleichen Werkstueck |
US3286855A (en) | 1965-06-01 | 1966-11-22 | Standard Trailer Company | Crane extension and resulting crane assembly |
US3553228A (en) * | 1967-09-26 | 1971-01-05 | Colgate Palmolive Co | 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles |
DE2040628A1 (de) | 1970-08-17 | 1972-02-24 | Fahlberg List Veb | Neue herbizide Mittel |
US3948928A (en) * | 1972-03-17 | 1976-04-06 | Dainippon Pharmaceutical Co., Ltd. | 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof |
JPS5621033B2 (hr) | 1973-09-05 | 1981-05-16 | ||
FR2323683A1 (fr) | 1975-09-11 | 1977-04-08 | Philagro Sa | Nouveaux derives d'amidoximes, leur preparation et les compositions qui les contiennent |
GB1501529A (en) * | 1975-09-11 | 1978-02-15 | Philagro Sa | Derivatives of amidoximes |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4323681A (en) * | 1980-09-29 | 1982-04-06 | American Home Products Corporation | 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
JPS58208275A (ja) | 1982-05-20 | 1983-12-03 | Lion Corp | 5−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤 |
DE3462259D1 (de) | 1983-07-22 | 1987-03-05 | Bayer Ag | Substituted furazans |
US4507485A (en) | 1984-01-23 | 1985-03-26 | Bristol-Myers Company | 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity |
JPS60193968A (ja) | 1984-03-13 | 1985-10-02 | Toyo Jozo Co Ltd | シクロペンテン環を有するイミダゾ−ルアミドオキシムおよびその製造法 |
JPS6259283A (ja) | 1985-09-10 | 1987-03-14 | Kaken Pharmaceut Co Ltd | セフアロスポリン化合物 |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
JP2696342B2 (ja) * | 1988-06-27 | 1998-01-14 | 日本曹達株式会社 | アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤 |
EP0352832B1 (en) | 1988-07-05 | 1992-05-06 | Akzo N.V. | Compounds with bronchodilator activity |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
JPH0420710A (ja) | 1990-05-12 | 1992-01-24 | Hitachi Home Tec Ltd | ポットバーナの運転制御装置 |
JPH04297449A (ja) | 1991-03-27 | 1992-10-21 | Hokko Chem Ind Co Ltd | N−ヒドロキシベンジルグアニジン誘導体および農園芸用殺菌剤 |
JPH05186458A (ja) | 1991-04-26 | 1993-07-27 | Japan Tobacco Inc | 新規なベンゾピラン誘導体 |
FR2677019B1 (fr) | 1991-05-27 | 1994-11-25 | Pf Medicament | Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique. |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
JP2709677B2 (ja) * | 1992-06-19 | 1998-02-04 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
FR2720396B1 (fr) * | 1994-05-27 | 1996-06-28 | Adir | Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5731315A (en) | 1995-06-07 | 1998-03-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds |
ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
BR9610988A (pt) | 1995-10-17 | 1999-04-06 | Astra Pharma Prod | Composto uso do mesmo fomulação farmacêutica e processo para produção do composto |
WO1997030047A1 (en) | 1996-02-17 | 1997-08-21 | Agrevo Uk Limited | Fungicidal 1,2,4-oxadiazoles and analogues |
US5955495A (en) | 1996-05-03 | 1999-09-21 | Hoffmann-La Roche Inc. | Method of treating diseases of the CNS |
JPH11171702A (ja) | 1997-09-24 | 1999-06-29 | Takeda Chem Ind Ltd | 害虫防除方法 |
AU1628599A (en) | 1997-12-05 | 1999-06-28 | Medical College Of Georgia Research Institute, Inc. | Regulation of t cell-mediated immunity by tryptophan |
ES2213929T3 (es) | 1997-12-10 | 2004-09-01 | Dainippon Ink And Chemicals, Inc. | Derivados de oximas y productos quimicos para uso agricola que incluyen los mismos. |
AR018424A1 (es) | 1998-06-02 | 2001-11-14 | Sumitomo Chem Takeda Agro Co | Compuesto oxadiazolina, composicion agroquimica que lo comprende y uso del mismo para la preparacion de dicha composicion |
DE69942097D1 (de) | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
FR2784678B1 (fr) * | 1998-09-23 | 2002-11-29 | Sod Conseils Rech Applic | Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
CN100354271C (zh) | 1999-03-03 | 2007-12-12 | 三进制药株式会社 | 哌嗪衍生物及其制备方法 |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
EP1165601A2 (de) | 1999-04-09 | 2002-01-02 | Basf Aktiengesellschaft | Prodrugs von thrombininhibitoren |
CN1164574C (zh) | 1999-05-24 | 2004-09-01 | 三菱制药株式会社 | 苯氧基丙胺类化合物 |
JP2001158785A (ja) | 1999-11-30 | 2001-06-12 | Takeda Chem Ind Ltd | 農薬組成物 |
JP2001158786A (ja) | 1999-11-30 | 2001-06-12 | Takeda Chem Ind Ltd | 哺乳動物の外部寄生虫防除剤 |
CA2397575A1 (en) * | 2000-01-13 | 2001-07-19 | Tularik Inc. | Antibacterial agents |
JP2001233861A (ja) | 2000-02-22 | 2001-08-28 | Ube Ind Ltd | ピラゾールオキシム化合物、その製法及び用途 |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
PT1294358E (pt) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | Processo de moagem por via humida |
GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
CZ20033475A3 (en) | 2001-06-18 | 2004-05-12 | Appliedáresearchásystemsáarsáholdingán@V | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists. |
CA2466243A1 (en) | 2001-09-19 | 2003-03-27 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
WO2003035092A1 (en) * | 2001-10-26 | 2003-05-01 | Angiolab Inc. | Composition containing horse chestnut extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
KR20090087139A (ko) | 2001-10-30 | 2009-08-14 | 노파르티스 아게 | Flt3 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체 |
CN101001857B (zh) | 2002-01-22 | 2011-06-22 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
JP2005529850A (ja) | 2002-02-19 | 2005-10-06 | ファルマシア・イタリア・エス・ピー・エー | 三環系ピラゾール誘導体、その製造方法および抗腫瘍剤としてのその使用 |
GB0208224D0 (en) | 2002-04-10 | 2002-05-22 | Celltech R&D Ltd | Chemical compounds |
WO2003087347A1 (en) | 2002-04-12 | 2003-10-23 | Medical College Of Georgia Research Institute, Inc. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
BR0311419A (pt) | 2002-05-28 | 2005-04-05 | Dimensional Pharm Inc | Amidinas de tiofeno suas composições e métodos de tratamento de doenças e condições mediadas por complemento |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
JP4020710B2 (ja) | 2002-06-25 | 2007-12-12 | 株式会社ミツバ | ドアミラーセットプレート |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
US7015321B2 (en) | 2002-10-12 | 2006-03-21 | The Scripps Research Institute | Synthesis of non-symmetrical sulfamides using burgess-type reagents |
AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
JP2006521377A (ja) * | 2003-03-27 | 2006-09-21 | ランケナー インスティテュート フォー メディカル リサーチ | 新型ido阻害剤とその使用方法 |
US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
CA2528551A1 (en) | 2003-06-13 | 2005-01-13 | Biogen Idec Ma Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
US7157476B2 (en) | 2003-08-20 | 2007-01-02 | Vertex Pharmaceuticals Incorporated | Aminofurazan compounds useful as protein kinase inhibitors |
AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
MY144044A (en) | 2004-06-10 | 2011-07-29 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
PL1801108T3 (pl) | 2004-09-08 | 2013-04-30 | Mitsubishi Tanabe Pharma Corp | Związki morfolinowe do leczenia stanów zapalnych |
KR20070085433A (ko) | 2004-11-24 | 2007-08-27 | 노파르티스 아게 | Jak 저해제들과 bcr-abl, flt-3, fak 또는raf 키나제 저해제들 중 하나 이상의 조합물 |
US8193359B2 (en) | 2004-12-24 | 2012-06-05 | Prosidion Limited | G-protein coupled receptor agonists |
US7429667B2 (en) * | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
SI2439273T1 (sl) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
SI1879573T1 (sl) | 2005-05-10 | 2013-04-30 | Incyte Corporation Experimental Station | Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te |
WO2006133417A1 (en) | 2005-06-07 | 2006-12-14 | Valeant Pharmaceuticals International | Phenylamino isothiazole carboxamidines as mek inhibitors |
KR20080026198A (ko) | 2005-06-30 | 2008-03-24 | 안트로제네시스 코포레이션 | 태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원 |
DE102005060466A1 (de) | 2005-12-17 | 2007-06-28 | Bayer Cropscience Ag | Carboxamide |
ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
US20070203140A1 (en) * | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
JP4297449B2 (ja) | 2006-05-12 | 2009-07-15 | 株式会社サクラクレパス | 墨汁 |
US20080146624A1 (en) * | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
CL2007002650A1 (es) * | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロサイクル |
WO2008036643A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008058178A1 (en) | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Lxr 및 fxr 조절자 |
CL2008000066A1 (es) * | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
KR20100095020A (ko) | 2007-12-19 | 2010-08-27 | 암젠 인크 | 세포 주기 억제제로서의 융합된 피리딘, 피리미딘 및 트리아진 화합물 |
CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
NO2824100T3 (hr) | 2008-07-08 | 2018-07-21 | ||
PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
DK2632467T3 (en) | 2010-10-25 | 2016-08-15 | G1 Therapeutics Inc | CDK inhibitors |
PT2688887E (pt) | 2011-03-23 | 2015-07-06 | Amgen Inc | Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3 |
US10034939B2 (en) | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
JP6357475B2 (ja) | 2013-07-12 | 2018-07-11 | 日本ケミファ株式会社 | P2x4受容体拮抗剤 |
ME03792B (me) | 2013-11-08 | 2021-04-20 | Incyte Holdings Corp | Postupak sinteze inhibitora indolamin 2,3-dioksigenaze |
KR20220153677A (ko) | 2014-02-04 | 2022-11-18 | 인사이트 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합 |
KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
MX2018001227A (es) | 2015-07-30 | 2018-03-26 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas. |
WO2017040864A1 (en) | 2015-09-01 | 2017-03-09 | First Wave Biopharma | Methods and compositions for treating conditions associated with an abnormal inflammatory responses |
MX2018005600A (es) | 2015-11-04 | 2018-11-09 | Incyte Corp | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. |
AU2020319875A1 (en) | 2019-08-01 | 2022-02-17 | Incyte Corporation | A dosing regimen for an IDO inhibitor |
WO2021222257A1 (en) | 2020-04-27 | 2021-11-04 | Armata Pharmaceuticals, Inc. | Bacteriophage compositions for treating pseudomonas infection |
-
2006
- 2006-05-09 SI SI200631540T patent/SI1879573T1/sl unknown
- 2006-05-09 CA CA2606783A patent/CA2606783C/en active Active
- 2006-05-09 PL PL06759438T patent/PL1879573T3/pl unknown
- 2006-05-09 NZ NZ562919A patent/NZ562919A/en unknown
- 2006-05-09 BR BR122020016659A patent/BR122020016659B8/pt active IP Right Grant
- 2006-05-09 SG SG10201809390QA patent/SG10201809390QA/en unknown
- 2006-05-09 JP JP2008511287A patent/JP4990270B2/ja active Active
- 2006-05-09 WO PCT/US2006/017983 patent/WO2006122150A1/en active Application Filing
- 2006-05-09 ME MEP-2016-96A patent/ME02461B/me unknown
- 2006-05-09 UA UAA200713720A patent/UA99897C2/ru unknown
- 2006-05-09 US US11/430,441 patent/US8034953B2/en active Active
- 2006-05-09 EA EA200702455A patent/EA026785B1/ru unknown
- 2006-05-09 DK DK12178315.3T patent/DK2559690T3/en active
- 2006-05-09 BR BRPI0608604A patent/BRPI0608604B8/pt active IP Right Grant
- 2006-05-09 KR KR1020137024999A patent/KR101562549B1/ko active IP Right Grant
- 2006-05-09 RS RS20130096A patent/RS52711B/en unknown
- 2006-05-09 EP EP06759438A patent/EP1879573B1/en active Active
- 2006-05-09 CN CN201210562826.8A patent/CN103130735B/zh active Active
- 2006-05-09 AU AU2006244068A patent/AU2006244068B9/en active Active
- 2006-05-09 KR KR1020077026204A patent/KR101386494B1/ko active IP Right Grant
- 2006-05-09 MX MX2007013977A patent/MX2007013977A/es active IP Right Grant
- 2006-05-09 PT PT121783153T patent/PT2559690T/pt unknown
- 2006-05-09 PT PT67594382T patent/PT1879573E/pt unknown
- 2006-05-09 SG SG2013079512A patent/SG195607A1/en unknown
- 2006-05-09 EP EP16155113.0A patent/EP3085697A1/en not_active Withdrawn
- 2006-05-09 DK DK06759438.2T patent/DK1879573T3/da active
- 2006-05-09 GE GEAP200610418A patent/GEP20217221B/en unknown
- 2006-05-09 ES ES06759438T patent/ES2401482T3/es active Active
- 2006-05-09 EP EP12178315.3A patent/EP2559690B1/en active Active
- 2006-05-09 SG SG201002836-3A patent/SG161310A1/en unknown
- 2006-05-09 RS RS20160440A patent/RS54876B1/sr unknown
- 2006-05-09 SI SI200632056A patent/SI2559690T1/sl unknown
- 2006-05-09 MY MYPI20062122A patent/MY153424A/en unknown
- 2006-05-09 ES ES12178315.3T patent/ES2578404T3/es active Active
- 2006-05-09 CN CNA2006800243261A patent/CN101212967A/zh active Pending
- 2006-05-09 HU HUE12178315A patent/HUE029214T2/en unknown
- 2006-05-09 PL PL12178315.3T patent/PL2559690T3/pl unknown
- 2006-05-10 TW TW095116584A patent/TWI377060B/zh active
- 2006-05-10 AR AR20060101876A patent/AR054271A1/es active IP Right Grant
-
2007
- 2007-10-25 IL IL186957A patent/IL186957A/en active IP Right Grant
- 2007-10-30 CR CR9485A patent/CR9485A/es unknown
- 2007-11-08 NO NO20075693A patent/NO340487B1/no unknown
- 2007-11-09 ZA ZA200709698A patent/ZA200709698B/xx unknown
-
2008
- 2008-07-21 HK HK08108013.8A patent/HK1117392A1/xx unknown
-
2011
- 2011-08-29 US US13/220,406 patent/US8372870B2/en active Active
-
2012
- 2012-03-08 JP JP2012052002A patent/JP5615308B2/ja active Active
-
2013
- 2013-01-04 US US13/734,263 patent/US8846726B2/en active Active
- 2013-03-13 HR HRP20130220TT patent/HRP20130220T1/hr unknown
- 2013-03-14 CY CY20131100225T patent/CY1113989T1/el unknown
- 2013-08-19 HK HK13109628.6A patent/HK1182381A1/zh unknown
-
2014
- 2014-04-28 IL IL232313A patent/IL232313A/en active IP Right Grant
- 2014-09-05 US US14/478,622 patent/US20140377292A1/en not_active Abandoned
-
2016
- 2016-05-19 HR HRP20160537TT patent/HRP20160537T1/hr unknown
- 2016-06-24 CY CY20161100569T patent/CY1117681T1/el unknown
-
2017
- 2017-04-18 NO NO20170633A patent/NO342140B1/no unknown
- 2017-06-26 US US15/632,986 patent/US10208002B2/en active Active
-
2019
- 2019-01-10 US US16/244,310 patent/US11192868B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20130220T1 (hr) | Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih | |
JP2010504342A5 (hr) | ||
RU2403247C2 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
RU2388750C2 (ru) | Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина | |
JP2007519754A5 (hr) | ||
RU2007107189A (ru) | Производные арилпиридина | |
RU2008112221A (ru) | Соединения ряда изоиндолимидов, их композиции и способы применения | |
JP2005526723A5 (hr) | ||
HRP20161085T1 (hr) | Sulfonamid derivati kao bcl-2 selektivni agensi za induciranje apoptoze namijenjeni liječenju raka i imunih bolesti | |
RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
JP2008509910A5 (hr) | ||
RU2006101053A (ru) | Производные бензамида или соль указанного производного | |
RU2009116670A (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
RU2005121897A (ru) | Производные аминоиндазолов и их применение в качестве ингибиторов киназ | |
HRP20150442T1 (hr) | Sredstva za izazivanje apoptoze za lijeäśenje raka i imunih i autoimunih bolesti | |
CA2618511A1 (en) | Novel benzothiazolone derivatives | |
CA2582029A1 (en) | Aryl nitrogen-containing bicyclic compounds and methods of use | |
RU2008132966A (ru) | Производные циклогексилпиперазинилметанона и их применение в качестве модуляторов гистамин н3 рецептора | |
RU2004136977A (ru) | Производные пиридазин-3(2h)-она в качестве ингибиторов фосфодиэстеразы 4 (pde4) | |
RU2011153772A (ru) | Фторированные аминотриазольные производные | |
RU2007141346A (ru) | Диарилсульфонсульфонамиды и их применение | |
RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
JP2009537543A5 (hr) | ||
JP2019507179A5 (hr) | ||
CA2573413A1 (en) | Histone deacetylase inhibitors |